Corporate Snapshot: Wuxi Acryl and Peer Performance
The Shanghai-listed Wuxi Acryl (603722.SS) finished the most recent trading day with no change, holding steady at CNY 25.45. The stock’s market capitalization currently sits at CNY 2.5 billion, with 97.7 million shares outstanding. In the past 24 hours, the exchange volume for Wuxi Acryl reached CNY 42.2 million.
Over the last month, the share price has slipped by 13.32 %, signalling a bearish trend that investors should monitor. The 200‑day simple moving average sits at CNY 31.98, underscoring the recent downward drift. The stock’s 52‑week high of CNY 47.92 (achieved on 07 July 2026) and low of CNY 24.52 (on 19 October 2026) illustrate its volatility over the year.
Peer Performance in the Last 24 Hours
| Company | Symbol | Price (CNY) | Market Cap (CNY) | P/E | Recent News |
|---|---|---|---|---|---|
| Shenyang Xingqi Pharmaceuticals | 300573.SZ | 34.83 | 3 bn | 15.48 | Launched a lower‑price 0.01 % atropine sulfate eye‑drop; price fell 20 % to improve patient access. |
| Risuntek | 002981.SZ | 22.18 | 3 bn | 110.4 | No major news; price unchanged. |
| Shanghai Titan Scientific | 688133.SS | 18.57 | 3 bn | — | No major news; price unchanged. |
| Hualan Biological Engineering | 002007.SZ | 12.89 | 3.3 bn | 29.36 | No major news; price unchanged. |
| Gongda Keya | 301197.SZ | 26.31 | 3 bn | 150.82 | No major news; price unchanged. |
Narrative Insights
Wuxi Acryl’s flat performance today reflects a broader trend of consolidation among its peers, many of whom traded unchanged as well. The company’s recent decline of over 13 % since the end of last month invites scrutiny of its fundamentals and strategic direction. While the 200‑day moving average remains above the current price, the sharp drop suggests that short‑term momentum may be waning.
Shenyang Xingqi Pharmaceuticals’ decision to reduce the price of its atropine sulfate eye drops is a strategic pivot aimed at broadening market penetration. By lowering costs, the company hopes to capture a larger share of the low‑dose myopia treatment market, which is becoming increasingly competitive. This move may have limited impact on the stock’s valuation in the immediate term, but it signals a willingness to balance affordability with growth.
In contrast, Risuntek, Shanghai Titan Scientific, Hualan Biological Engineering, and Gongda Keya have all traded at a steady pace without announcing significant events. Their high price‑to‑earnings ratios—particularly Risuntek’s 110.4 and Gongda Keya’s 150.82—suggest that investors are pricing in future earnings potential, although the lack of recent catalysts could temper enthusiasm.
Takeaway
For investors watching the Chinese biotech and pharmaceutical landscape, Wuxi Acryl’s stability today is a reminder of the importance of monitoring underlying fundamentals and market sentiment. The peer group’s price stability, coupled with Shenyang Xingqi’s pricing strategy, underscores the sector’s shifting dynamics: firms are increasingly leveraging pricing and product diversification to secure market share. As the market moves forward, analysts will likely focus on whether these strategic adjustments translate into tangible gains in revenue and profitability.